[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 691,823
  • Shares Outstanding, K 59,384
  • Annual Sales, $ 106,470 K
  • Annual Income, $ 83,230 K
  • EBIT $ 84 M
  • EBITDA $ 143 M
  • 60-Month Beta 0.91
  • Price/Sales 6.62
  • Price/Cash Flow 12.55
  • Price/Book 3.22

Options Overview Details

View History
  • Implied Volatility 58.85% (+2.75%)
  • Historical Volatility 95.14%
  • IV Percentile 7%
  • IV Rank 4.03%
  • IV High 339.85% on 03/03/26
  • IV Low 47.05% on 08/19/26
  • Expected Move (DTE 24) 1.23 (10.24%)
  • Put/Call Vol Ratio 0.72
  • Today's Volume 5,744
  • Volume Avg (30-Day) 6,237
  • Put/Call OI Ratio 1.40
  • Today's Open Interest 58,012
  • Open Int (30-Day) 57,409
  • Expected Range 10.81 to 13.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.14
  • Number of Estimates 3
  • High Estimate $0.15
  • Low Estimate $0.11
  • Prior Year $-0.01
  • Growth Rate Est. (year over year) +1,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.34 +28.91%
on 07/31/26
12.32 -2.27%
on 08/06/26
+2.52 (+26.40%)
since 07/24/26
3-Month
9.10 +32.31%
on 07/24/26
15.03 -19.92%
on 07/08/26
+2.01 (+20.04%)
since 05/22/26
52-Week
7.16 +68.16%
on 09/17/25
15.03 -19.92%
on 07/08/26
+2.68 (+28.63%)
since 08/25/25

Most Recent Stories

More News
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people...

ZVRA : 12.04 (+3.35%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised...

ZVRA : 12.04 (+3.35%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics: Q2 Earnings Snapshot

Zevra Therapeutics: Q2 Earnings Snapshot

ZVRA : 12.04 (+3.35%)
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position ...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics' Profit Streak Continues Tomorrow, But Revenue Growth Remains the Question

Barchart Research What to Expect from ZVRA Earnings ZVRA Generated August 4, 2026 Current Price $10.52 EPS Estimate $$0.08 Consensus Rating Strong Buy Average Move 7.81% Zevra Therapeutics' Profit Streak...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the  European Medicines Agency's Committee for Medicinal...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 12.57
2nd Resistance Point 12.36
1st Resistance Point 12.20
Last Price 12.04
1st Support Level 11.83
2nd Support Level 11.62
3rd Support Level 11.46

See More

52-Week High 15.03
Last Price 12.04
Fibonacci 61.8% 12.03
Fibonacci 50% 11.10
Fibonacci 38.2% 10.17
52-Week Low 7.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.